The BET inhibitor I-BET762 inhibits pancreatic ductal adenocarcinoma cell proliferation and enhances the therapeutic effect of gemcitabine

As one of the most fatal malignancies, pancreatic ductal adenocarcinoma (PDAC) has significant resistance to the currently available treatment approaches. Gemcitabine, the standard chemotherapeutic agent for locally advanced and metastatic PDAC, has limited efficacy, which is attributed to innate/ac...

Descripción completa

Detalles Bibliográficos
Autores principales: Xie, Fang, Huang, Mei, Lin, Xiansheng, Liu, Chenhai, Liu, Zhen, Meng, Futao, Wang, Chao, Huang, Qiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5970200/
https://www.ncbi.nlm.nih.gov/pubmed/29802402
http://dx.doi.org/10.1038/s41598-018-26496-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5970200/
https://www.ncbi.nlm.nih.gov/pubmed/29802402
http://dx.doi.org/10.1038/s41598-018-26496-0

Ejemplares similares